Facebook
Twitter
Telegram
Report an ErrorCorcept Therapeutics Incorporated Balance Sheet 2011-2024 | CORT
Annual Balance Sheet Corcept Therapeutics Incorporated
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | - | -27.8 M | -41.6 M | -31.1 M | -36.9 M | -25.5 M | -14.8 M | -49.1 M | -90.4 M | -39.6 M |
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
151 K | 1.14 M | 526 K | 2.05 M | 1.56 M | - | - | 14.7 M | 15 M | 9.42 M | 5.74 M | 2.65 M | - |
Total Non Current Liabilities |
- | - | - | - | 2.29 M | 239 K | - | - | 12.6 M | 24.5 M | 29.3 M | 29 M | - |
Total Current Liabilities |
105 M | 72.5 M | 47.5 M | 47.5 M | 38.8 M | 35.6 M | 29.6 M | 27.4 M | 20.9 M | 13.6 M | 12.7 M | 8.36 M | 5.03 M |
Total Liabilities |
115 M | 81.6 M | 48 M | 48.4 M | 41.1 M | 35.8 M | 29.6 M | 27.4 M | 33.4 M | 38 M | 42.1 M | 37.4 M | 5.03 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | 158 K | 33 K | 25 K | 16 K | - |
Retained Earnings |
403 M | 296 M | 195 M | 82.5 M | -23.6 M | -118 M | -193 M | -322 M | -330 M | -324 M | -293 M | -247 M | -209 M |
Total Assets |
622 M | 583 M | 424 M | 572 M | 412 M | 312 M | 221 M | 68.8 M | 51.9 M | 34.6 M | 63.1 M | 99.2 M | 39.8 M |
Cash and Cash Equivalents |
136 M | 66.3 M | 77.6 M | 76.2 M | 31.3 M | 41.6 M | 31.1 M | 51.5 M | 40.4 M | 24.2 M | 54.9 M | 93 M | 39.6 M |
Book Value |
507 M | 502 M | 376 M | 523 M | 371 M | 276 M | 191 M | 41.4 M | 18.5 M | -3.39 M | 21 M | 61.8 M | 34.8 M |
Total Shareholders Equity |
507 M | 502 M | 376 M | 523 M | 371 M | 276 M | 191 M | 41.4 M | 18.5 M | -3.39 M | 21 M | 61.8 M | 34.8 M |
All numbers in USD currency
Quarterly Balance Sheet Corcept Therapeutics Incorporated
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | 552 K | - | - | - | - | 501 K | 501 K | 501 K | 501 K | 1.9 M | 1.9 M | 1.9 M | 1.9 M | - | - | - | - | - | - | - | - | - | - | - | - | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 24.5 M | 24.5 M | 24.5 M | 24.5 M | 29.3 M | 29.3 M | 29.3 M | 29.3 M | 29 M | 29 M | 29 M | 29 M | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
108 M | 132 M | 103 M | 88.3 M | - | 59.9 M | - | 60.3 M | 48 M | 45.2 M | 45.8 M | 41.6 M | 48.4 M | 48.4 M | 48.4 M | 48.4 M | 41.1 M | 41.1 M | 41.1 M | 41.1 M | 35.8 M | 35.8 M | 35.8 M | 35.8 M | 29.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 158 K | 158 K | 158 K | 158 K | 33 K | 33 K | 33 K | 33 K | 25 K | 25 K | 25 K | 25 K | 16 K | 16 K | 16 K | 16 K | - | - | - | - |
Retained Earnings |
430 M | 371 M | 340 M | 312 M | - | 280 M | - | 218 M | 195 M | 163 M | 132 M | 106 M | 82.5 M | 82.5 M | 82.5 M | 82.5 M | -23.6 M | -23.6 M | -23.6 M | -23.6 M | -118 M | -118 M | -118 M | -118 M | -193 M | -193 M | -193 M | -193 M | -322 M | -322 M | -322 M | -322 M | -330 M | -330 M | -330 M | -330 M | -324 M | -324 M | -324 M | -324 M | -293 M | -293 M | -293 M | -293 M | -247 M | -247 M | -247 M | -247 M | -209 M | -199 M | -192 M | - |
Total Assets |
656 M | 594 M | 525 M | 618 M | - | 533 M | - | 468 M | 424 M | 585 M | 568 M | 552 M | 572 M | 572 M | 572 M | 572 M | 412 M | 412 M | 412 M | 412 M | 312 M | 312 M | 312 M | 312 M | 221 M | 221 M | 221 M | 221 M | 68.8 M | 68.8 M | 68.8 M | 68.8 M | 51.9 M | 51.9 M | 51.9 M | 51.9 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 63.1 M | 63.1 M | 63.1 M | 63.1 M | 99.2 M | 99.2 M | 99.2 M | 99.2 M | 39.8 M | 39.8 M | 39.8 M | 39.8 M |
Cash and Cash Equivalents |
150 M | 112 M | 172 M | 300 M | - | 50.2 M | 35.3 M | 61.9 M | 77.6 M | 94.7 M | 95.4 M | 52.4 M | 76.2 M | 76.2 M | 76.2 M | 76.2 M | 31.3 M | 31.3 M | 31.3 M | 31.3 M | 41.6 M | 41.6 M | 41.6 M | 41.6 M | 31.1 M | 31.1 M | 31.1 M | 31.1 M | 51.5 M | 51.5 M | 51.5 M | 51.5 M | 40.4 M | 40.4 M | 40.4 M | 40.4 M | 24.2 M | 24.2 M | 24.2 M | 24.2 M | 54.9 M | 54.9 M | 54.9 M | 54.9 M | 93 M | 93 M | 93 M | 93 M | 39.6 M | 39.6 M | 39.6 M | 39.6 M |
Book Value |
548 M | 462 M | 422 M | 530 M | - | 473 M | - | 408 M | 376 M | 540 M | 523 M | 511 M | 523 M | 523 M | 523 M | 523 M | 371 M | 371 M | 371 M | 371 M | 276 M | 276 M | 276 M | 276 M | 191 M | 221 M | 221 M | 221 M | 68.8 M | 68.8 M | 68.8 M | 68.8 M | 51.9 M | 51.9 M | 51.9 M | 51.9 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 63.1 M | 63.1 M | 63.1 M | 63.1 M | 99.2 M | 99.2 M | 99.2 M | 99.2 M | 39.8 M | 39.8 M | 39.8 M | 39.8 M |
Total Shareholders Equity |
548 M | 462 M | 422 M | 530 M | - | 473 M | 442 M | 408 M | 376 M | 540 M | 523 M | 511 M | 523 M | 523 M | 523 M | 523 M | 371 M | 371 M | 371 M | 371 M | 276 M | 276 M | 276 M | 276 M | 191 M | 191 M | 191 M | 191 M | 41.4 M | 41.4 M | 41.4 M | 41.4 M | 18.5 M | 18.5 M | 18.5 M | 18.5 M | -3.39 M | -3.39 M | -3.39 M | -3.39 M | 21 M | 21 M | 21 M | 21 M | 61.8 M | 61.8 M | 61.8 M | 61.8 M | 34.8 M | 34.8 M | 34.8 M | 34.8 M |
All numbers in USD currency